CIK 0001833214 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SAB Biotherapeutics, Inc.
Sign in to watch- Ticker
- SABS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 853899721
- Phone
- 305-845-2813
- Business address
- 777 W 41ST ST, SUITE 401, MIAMI BEACH, FL, 33140
- Former names
- Big Cypress Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 16 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-17 | Kropotova Alexandra CHIEF MEDICAL OFFICER | Shares withheld for taxes | −473 | 41,853 | ||
| 2026-06-25 | Kropotova Alexandra CHIEF MEDICAL OFFICER | Shares withheld for taxes | −988 | 42,308 | ||
| 2026-03-24 | Kropotova Alexandra CHIEF MEDICAL OFFICER | Shares withheld for taxes | −988 | 43,296 | ||
| 2026-02-03 | Sullivan Eddie Joe PRESIDENT | Grant or award · Stock option (right to buy) | +3,000,000 | 3,000,000 | ||
| 2026-02-03 | Reich Samuel J CEO | Grant or award · Stock option (right to buy) | +4,800,000 | 4,800,000 | ||
| 2026-02-03 | Bausch Christoph Lawrence CHIEF OPERATING OFFICER | Grant or award · Stock option (right to buy) | +1,800,000 | 1,800,000 | ||
| 2026-02-03 | Kropotova Alexandra CHIEF MEDICAL OFFICER | Grant or award · Stock option (right to buy) | +2,400,000 | 2,400,000 | ||
| 2026-02-03 | To Lucy See Remarks | Grant or award · Stock option (right to buy) | +2,400,000 | 2,400,000 | ||
| 2026-01-05 | Jain Rita Director | Grant or award · Stock Option (right to buy) | +240,000 | 240,000 | ||
| 2026-01-05 | ZACCARDELLI DAVID Director | Grant or award · Stock Option (right to buy) | +240,000 | 240,000 | ||
| 2025-12-16 | SKYLER JAY S Director | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2025-12-16 | Polvino William James Director | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2025-12-16 | Lucera Erick Director | Grant or award · Stock option (right to buy) | +150,000 | 150,000 | ||
| 2025-12-16 | Ellias Helen K. Director | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2025-12-16 | Giberson Scott Director | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2025-12-16 | Link David Director | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2025-12-11 | Kropotova Alexandra CHIEF MEDICAL OFFICER | Shares withheld for taxes | −988 | 44,284 | ||
| 2025-09-29 | Moin Andrew Director | Option exercise | +1,740,000 | $1.75 | $3.0M | 2,198,457 |
| 2025-09-29 | Moin Andrew Director | Option exercise · Series B Convertible Preferred Stock | −17,400 | 211,100 | ||
| 2025-09-29 | Sessa Capital (Master), L.P. Director | Option exercise | +1,740,000 | $1.75 | $3.0M | 2,198,457 |
Page 1 of 9 · 172 trades